Sector revisions Merck & Co., Inc.

Equities

Delayed Nyse Other stock markets 16:00:02 2026-01-16 EST			5-day change	1st Jan Change
108.83 ^USD	-1.93%		-1.54%	+3.39%

09:34am	Guardant Health announces multi-year strategic collaboration agreement with Merck	RE
08:50am	Guardant Health, Inc. Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform	CI

Sector:

Location:

X axis:

Main competitors

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	MERCK & CO., INC.							27
	ELI LILLY AND COMPANY							28
	JOHNSON & JOHNSON							24
	ABBVIE INC.							27
	ROCHE HOLDING AG							19
	ASTRAZENECA PLC							20
	NOVARTIS AG							20
	NOVO NORDISK A/S							21
	AMGEN INC.							27
	GILEAD SCIENCES, INC.							26
	PFIZER INC.							24
	SANOFI							22
	BRISTOL-MYERS SQUIBB COMPANY							23
	VERTEX PHARMACEUTICALS INCORPORATED							25
	GSK PLC							19
	CHUGAI PHARMACEUTICAL CO., LTD.							14
	JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD							17
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							15
	ALNYLAM PHARMACEUTICALS, INC.							25
	Average							22
	Weighted average by Cap.							24